Laboratorio Reig Jofre S A : REIG JOFRE submits press release on the results of the third quarter of 2023
October 30, 2023 at 02:54 pm IST
Share
REIG JOFRE submits press release on the results of the third quarter of 2023
30 October 2023
REIG JOFRE increased 22% in revenue and 24% in EBITDA up to the 3rd quarter of 2023.
REIG JOFRE reaches 237 million euros of sales, 22% above the first nine months of 2022, due to the notable progression in the Specialty Pharmacare Division and the greater utilisation of the capacity of the new Barcelona plant. Profitability was also improved, with EBITDA growth of 24% to reach 26.2 million euros compared to 21.2 million euros up to September of the previous year.
The Specialty Pharmacare division, focused on the prescription medical product, could close with the highest growth in revenue by 34%. The division with the greatest weight in sales, Pharmaceutical Technologies, dedicated to injectable products and antibiotics, achieved a growth of 19%, whereas the Consumer Healthcare division, the consumer products division, under the FORTE PHARMA brand, in the French, Belgian and Spanish markets, as well as Reig Jofre's OTC products, grew by 11%.
REIG JOFRE consolidates a growth in sales and profitability of over 20% and expects to end the year with over 300 million euros in revenue. In June, it signed a four-year agreement with the EU capacity reserve for vaccine manufacturing in the event of a health emergency.
Laboratorio Reig Jofre SA published this content on 30 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 October 2023 09:23:40 UTC.
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.